Poor
Not Aligned
Patient Risk:
High
Summary
Only a small subset of the claims can be supported by the provided label excerpts (mainly lansoprazole mechanism and certain lansoprazole indications). Multiple claims about ranitidine (mechanism, indications, adverse effects, NDMA recall/unavailability, and comparative/transition statements) are not supported by the supplied prescribing information, and several safety-relevant statements (e.g., 'common side effects') are unverifiable from the provided label sections.
Category Scores
Accurate Statements
Lansoprazole is a proton pump inhibitor (PPI).
12.1 Mechanism of Action (PREVACID ... gastric acid-pump inhibitor ...)
Lansoprazole works by blocking the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.
12.1 Mechanism of Action (specific inhibition of the (H+, K+)-ATPase enzyme system ... blocks the final step of acid production)
Lansoprazole is used for pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES).
1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES)
Unsupported Statements
Ranitidine is a histamine-2 (H2) blocker.
No ranitidine-related statements are present in the provided label excerpts.
Lansoprazole works by irreversibly blocking the enzyme (H+/K+-ATPase) in the stomach lining that produces acid.
Provided label excerpt supports inhibition of (H+, K+)-ATPase and blockade of the final step of acid production, but does not state irreversibility.
Ranitidine works by blocking histamine, which stimulates acid production, thereby reducing the amount of acid released.
No ranitidine-related mechanism statements are present in the provided label excerpts.
PPIs, including lansoprazole, are generally more potent and effective than H2 blockers like ranitidine in suppressing gastric acid production.
No comparative potency/effectiveness statements vs H2 blockers are present in the provided label excerpts.
PPIs are preferred for moderate to severe acid reflux.
No such 'preference' guidance is present in the provided label excerpts.
PPIs are preferred for erosive esophagitis.
No such 'preference' guidance is present in the provided label excerpts.
H2 blockers are often used for milder symptoms or as an adjunct therapy.
No H2-blocker usage guidance is present in the provided label excerpts.
Both lansoprazole and ranitidine are prescribed to treat heartburn.
The provided label excerpts do not mention ranitidine and do not define/mention heartburn as an indication.
Both lansoprazole and ranitidine are prescribed to treat gastroesophageal reflux disease (GERD).
PREVACID (lansoprazole) GERD is mentioned, but ranitidine is not present in the provided label excerpts.
Both lansoprazole and ranitidine are prescribed to treat peptic ulcers.
PREVACID ulcer indications are present, but ranitidine is not present in the provided label excerpts.
Lansoprazole and ranitidine can be used to prevent ulcers caused by certain medications, like nonsteroidal anti-inflammatory drugs (NSAIDs).
NSAID-associated gastric ulcer risk reduction is supported for PREVACID, but ranitidine is not supported by the provided label excerpts.
Common side effects of lansoprazole can include diarrhea, constipation, headache, and nausea.
The provided label excerpts do not list 'common side effects' for lansoprazole.
Ranitidine side effects may include headache, diarrhea, constipation, and dizziness.
No ranitidine adverse reaction list is present in the provided label excerpts.
In 2019, ranitidine products were found to contain unacceptable levels of NDMA (a probable human carcinogen).
No NDMA recall/safety statements are present in the provided label excerpts.
The finding of unacceptable levels of NDMA in ranitidine led to widespread recalls and discontinuation of ranitidine products in many markets.
No NDMA recall/discontinuation statements are present in the provided label excerpts.
Lansoprazole has not faced similar safety concerns regarding NDMA contamination.
No NDMA contamination comparison statements are present in the provided label excerpts.
Following the recalls, patients previously using ranitidine often transition to other H2 blockers or PPIs; PPIs are frequently recommended as alternatives after ranitidine recalls; other H2 blockers not implicated are also recommended.
No post-recall transition/recommendation statements are present in the provided label excerpts.
Ranitidine is largely unavailable due to widespread recall.
No ranitidine availability statements are present in the provided label excerpts.
Lansoprazole is available in both prescription and over-the-counter formulations.
No formulation/OTC availability statements are present in the provided label excerpts.
Generic options of lansoprazole generally contribute to a lower cost.
No pricing or cost statements are present in the provided label excerpts.
Contradictions
Important Omissions
Contraindications/boxed warnings/warnings/precautions, drug interactions, and detailed dosage & administration were not addressed in the AI response, but these elements are relevant for label alignment and safety evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple safety- and therapy-relevant claims (especially those about ranitidine NDMA contamination/recalls/unavailability and ranitidine adverse effects/indications) are not supported by the provided FDA-label excerpts, making the overall response unreliable for label-compliant clinical use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Ranitidine-related mechanism, indications, adverse effects, NDMA recall/unavailability, and post-recall switching statements are unsupported by the supplied label excerpts; several lansoprazole mechanism details (irreversibility) are partially unsupported.
Suggested Improvement
Limit claims to what is supported in the provided PREVACID (lansoprazole) label excerpts (e.g., mechanism via (H+,K+)-ATPase inhibition and supported lansoprazole indications). Remove ranitidine-specific and comparative/preference statements unless ranitidine label content is supplied, and avoid unlabelled 'common side effects' lists.